1
|
Liu Y, Cui W, Liu H, Yao M, Shen W, Miao L, Wei J, Liang X, Zhang Y. Exploring the "gene-metabolite" network of ischemic stroke with blood stasis and toxin syndrome by integrated transcriptomics and metabolomics strategy. Sci Rep 2024; 14:11947. [PMID: 38789486 PMCID: PMC11126742 DOI: 10.1038/s41598-024-61633-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/01/2024] [Accepted: 05/08/2024] [Indexed: 05/26/2024] Open
Abstract
A research model combining a disease and syndrome can provide new ideas for the treatment of ischemic stroke. In the field of traditional Chinese medicine, blood stasis and toxin (BST) syndrome is considered an important syndrome seen in patients with ischemic stroke (IS). However, the biological basis of IS-BST syndrome is currently not well understood. Therefore, this study aimed to explore the biological mechanism of IS-BST syndrome. This study is divided into two parts: (1) establishment of an animal model of ischemic stroke disease and an animal model of BST syndrome in ischemic stroke; (2) use of omics methods to identify differentially expressed genes and metabolites in the models. We used middle cerebral artery occlusion (MCAO) surgery to establish the disease model, and utilized carrageenan combined with active dry yeast and MCAO surgery to construct the IS-BST syndrome model. Next, we used transcriptomics and metabolomics methods to explore the differential genes and metabolites in the disease model and IS-BST syndrome model. It is found that the IS-BST syndrome model exhibited more prominent characteristics of IS disease and syndrome features. Both the disease model and the IS-BST syndrome model share some common biological processes, such as thrombus formation, inflammatory response, purine metabolism, sphingolipid metabolism, and so on. Results of the "gene-metabolite" network revealed that the IS-BST syndrome model exhibited more pronounced features of complement-coagulation cascade reactions and amino acid metabolism disorders. Additionally, the "F2 (thrombin)-NMDAR/glutamate" pathway was coupled with the formation process of the blood stasis and toxin syndrome. This study reveals the intricate mechanism of IS-BST syndrome, offering a successful model for investigating the combination of disease and syndrome.
Collapse
Affiliation(s)
- Yue Liu
- Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China
| | - Wenqiang Cui
- Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China
- Department of Neurology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China
| | - Hongxi Liu
- Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China
| | - Mingjiang Yao
- Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China
- Beijing Key Laboratory of Pharmacology of Chinese Materia Region, Institute of Basic Medical Sciences, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing, China
| | - Wei Shen
- Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China
| | - Lina Miao
- Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China
| | - Jingjing Wei
- Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China.
| | - Xiao Liang
- Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China.
| | - Yunling Zhang
- Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China.
| |
Collapse
|
2
|
Hu X, Chen S, Ye S, Chen W, Zhou Y. New insights into the role of immunity and inflammation in diabetic kidney disease in the omics era. Front Immunol 2024; 15:1342837. [PMID: 38487541 PMCID: PMC10937589 DOI: 10.3389/fimmu.2024.1342837] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2023] [Accepted: 02/19/2024] [Indexed: 03/17/2024] Open
Abstract
Diabetic kidney disease (DKD) is becoming the leading cause of chronic kidney disease, especially in the industrialized world. Despite mounting evidence has demonstrated that immunity and inflammation are highly involved in the pathogenesis and progression of DKD, the underlying mechanisms remain incompletely understood. Substantial molecules, signaling pathways, and cell types participate in DKD inflammation, by integrating into a complex regulatory network. Most of the studies have focused on individual components, without presenting their importance in the global or system-based processes, which largely hinders clinical translation. Besides, conventional technologies failed to monitor the different behaviors of resident renal cells and immune cells, making it difficult to understand their contributions to inflammation in DKD. Recently, the advancement of omics technologies including genomics, epigenomics, transcriptomics, proteomics, and metabolomics has revolutionized biomedical research, which allows an unbiased global analysis of changes in DNA, RNA, proteins, and metabolites in disease settings, even at single-cell and spatial resolutions. They help us to identify critical regulators of inflammation processes and provide an overview of cell heterogeneity in DKD. This review aims to summarize the application of multiple omics in the field of DKD and emphasize the latest evidence on the interplay of inflammation and DKD revealed by these technologies, which will provide new insights into the role of inflammation in the pathogenesis of DKD and lead to the development of novel therapeutic approaches and diagnostic biomarkers.
Collapse
Affiliation(s)
- Xinrong Hu
- Department of Nephrology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
- Key Laboratory of Nephrology, National Health Commission and Guangdong Province, Guangzhou, China
| | - Sixiu Chen
- Department of Nephrology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
- Key Laboratory of Nephrology, National Health Commission and Guangdong Province, Guangzhou, China
| | - Siyang Ye
- Department of Nephrology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
- Key Laboratory of Nephrology, National Health Commission and Guangdong Province, Guangzhou, China
| | - Wei Chen
- Department of Nephrology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
- Key Laboratory of Nephrology, National Health Commission and Guangdong Province, Guangzhou, China
| | - Yi Zhou
- Department of Nephrology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China
- Key Laboratory of Nephrology, National Health Commission and Guangdong Province, Guangzhou, China
| |
Collapse
|
5
|
Torres-López C, Cuartero MI, García-Culebras A, de la Parra J, Fernández-Valle ME, Benito M, Vázquez-Reyes S, Jareño-Flores T, de Castro-Millán FJ, Hurtado O, Buckwalter MS, García-Segura JM, Lizasoain I, Moro MA. Ipsilesional Hippocampal GABA Is Elevated and Correlates With Cognitive Impairment and Maladaptive Neurogenesis After Cortical Stroke in Mice. Stroke 2023; 54:2652-2665. [PMID: 37694402 DOI: 10.1161/strokeaha.123.043516] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2022] [Accepted: 08/09/2023] [Indexed: 09/12/2023]
Abstract
BACKGROUND Cognitive dysfunction is a frequent stroke sequela, but its pathogenesis and treatment remain unresolved. Involvement of aberrant hippocampal neurogenesis and maladaptive circuitry remodeling has been proposed, but their mechanisms are unknown. Our aim was to evaluate potential underlying molecular/cellular events implicated. METHODS Stroke was induced by permanent occlusion of the middle cerebral artery occlusion in 2-month-old C57BL/6 male mice. Hippocampal metabolites/neurotransmitters were analyzed longitudinally by in vivo magnetic resonance spectroscopy. Cognitive function was evaluated with the contextual fear conditioning test. Microglia, astrocytes, neuroblasts, interneurons, γ-aminobutyric acid (GABA), and c-fos were analyzed by immunofluorescence. RESULTS Approximately 50% of mice exhibited progressive post-middle cerebral artery occlusion cognitive impairment. Notably, immature hippocampal neurons in the impaired group displayed more severe aberrant phenotypes than those from the nonimpaired group. Using magnetic resonance spectroscopy, significant bilateral changes in hippocampal metabolites, such as myo-inositol or N-acetylaspartic acid, were found that correlated, respectively, with numbers of glia and immature neuroblasts in the ischemic group. Importantly, some metabolites were specifically altered in the ipsilateral hippocampus suggesting its involvement in aberrant hippocampal neurogenesis and remodeling processes. Specifically, middle cerebral artery occlusion animals with higher hippocampal GABA levels displayed worse cognitive outcome. Implication of GABA in this setting was supported by the amelioration of ischemia-induced memory deficits and aberrant hippocampal neurogenesis after blocking pharmacologically GABAergic neurotransmission, an intervention which was ineffective when neurogenesis was inhibited. These data suggest that GABA exerts its detrimental effect, at least partly, by affecting morphology and integration of newborn neurons into the hippocampal circuits. CONCLUSIONS Hippocampal GABAergic neurotransmission could be considered a novel diagnostic and therapeutic target for poststroke cognitive impairment.
Collapse
Affiliation(s)
- Cristina Torres-López
- Neurovascular Pathophysiology, Cardiovascular Risk Factor and Brain Function Programme, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain (C.T.-L., M.I.C., A.G.-C., S.V.-R., T.J.-F., F.J.d.C.-M., O.H., M.A.M.)
- Unidad de Investigación Neurovascular, Departamento de Farmacología, Facultad de Medicina (C.T.-L., M.I.C., A.G.-C., J.d.l.P., S.V.-R., T.J.-F., F.J.d.C.-M., I.L., M.A.M.), Universidad Complutense de Madrid (UCM), Spain
- Instituto Universitario de Investigación en Neuroquímica (C.T.-L., M.I.C., A.G.-C., J.M.G.-S., I.L.), Universidad Complutense de Madrid (UCM), Spain
- Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain (C.T.-L., M.I.C., A.G.-C., I.L., M.A.M.)
| | - Maria I Cuartero
- Neurovascular Pathophysiology, Cardiovascular Risk Factor and Brain Function Programme, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain (C.T.-L., M.I.C., A.G.-C., S.V.-R., T.J.-F., F.J.d.C.-M., O.H., M.A.M.)
- Instituto Universitario de Investigación en Neuroquímica (C.T.-L., M.I.C., A.G.-C., J.M.G.-S., I.L.), Universidad Complutense de Madrid (UCM), Spain
- Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain (C.T.-L., M.I.C., A.G.-C., I.L., M.A.M.)
| | - Alicia García-Culebras
- Neurovascular Pathophysiology, Cardiovascular Risk Factor and Brain Function Programme, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain (C.T.-L., M.I.C., A.G.-C., S.V.-R., T.J.-F., F.J.d.C.-M., O.H., M.A.M.)
- Unidad de Investigación Neurovascular, Departamento de Farmacología, Facultad de Medicina (C.T.-L., M.I.C., A.G.-C., J.d.l.P., S.V.-R., T.J.-F., F.J.d.C.-M., I.L., M.A.M.), Universidad Complutense de Madrid (UCM), Spain
- Instituto Universitario de Investigación en Neuroquímica (C.T.-L., M.I.C., A.G.-C., J.M.G.-S., I.L.), Universidad Complutense de Madrid (UCM), Spain
- Departamento de Biología Celular, Facultad de Medicina (A.G.-C.), Universidad Complutense de Madrid (UCM), Spain
- Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain (C.T.-L., M.I.C., A.G.-C., I.L., M.A.M.)
| | - Juan de la Parra
- Unidad de Investigación Neurovascular, Departamento de Farmacología, Facultad de Medicina (C.T.-L., M.I.C., A.G.-C., J.d.l.P., S.V.-R., T.J.-F., F.J.d.C.-M., I.L., M.A.M.), Universidad Complutense de Madrid (UCM), Spain
| | - María E Fernández-Valle
- Infraestructura Científica y Técnica Singular (ICTS) Centro de Bioimagen Complutense (M.E.F.-V., J.M.G.-S.), Universidad Complutense de Madrid (UCM), Spain
| | - Marina Benito
- Hospital Nacional de Parapléjicos de Toledo, Spain (M.B.)
| | - Sandra Vázquez-Reyes
- Neurovascular Pathophysiology, Cardiovascular Risk Factor and Brain Function Programme, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain (C.T.-L., M.I.C., A.G.-C., S.V.-R., T.J.-F., F.J.d.C.-M., O.H., M.A.M.)
- Unidad de Investigación Neurovascular, Departamento de Farmacología, Facultad de Medicina (C.T.-L., M.I.C., A.G.-C., J.d.l.P., S.V.-R., T.J.-F., F.J.d.C.-M., I.L., M.A.M.), Universidad Complutense de Madrid (UCM), Spain
| | - Tania Jareño-Flores
- Neurovascular Pathophysiology, Cardiovascular Risk Factor and Brain Function Programme, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain (C.T.-L., M.I.C., A.G.-C., S.V.-R., T.J.-F., F.J.d.C.-M., O.H., M.A.M.)
- Unidad de Investigación Neurovascular, Departamento de Farmacología, Facultad de Medicina (C.T.-L., M.I.C., A.G.-C., J.d.l.P., S.V.-R., T.J.-F., F.J.d.C.-M., I.L., M.A.M.), Universidad Complutense de Madrid (UCM), Spain
| | - Francisco J de Castro-Millán
- Neurovascular Pathophysiology, Cardiovascular Risk Factor and Brain Function Programme, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain (C.T.-L., M.I.C., A.G.-C., S.V.-R., T.J.-F., F.J.d.C.-M., O.H., M.A.M.)
- Unidad de Investigación Neurovascular, Departamento de Farmacología, Facultad de Medicina (C.T.-L., M.I.C., A.G.-C., J.d.l.P., S.V.-R., T.J.-F., F.J.d.C.-M., I.L., M.A.M.), Universidad Complutense de Madrid (UCM), Spain
| | - Olivia Hurtado
- Neurovascular Pathophysiology, Cardiovascular Risk Factor and Brain Function Programme, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain (C.T.-L., M.I.C., A.G.-C., S.V.-R., T.J.-F., F.J.d.C.-M., O.H., M.A.M.)
| | - Marion S Buckwalter
- Department of Neurology and Neurological Sciences, Stanford University School of Medicine, CA (M.S.B.)
| | - Juan M García-Segura
- Instituto Universitario de Investigación en Neuroquímica (C.T.-L., M.I.C., A.G.-C., J.M.G.-S., I.L.), Universidad Complutense de Madrid (UCM), Spain
- Infraestructura Científica y Técnica Singular (ICTS) Centro de Bioimagen Complutense (M.E.F.-V., J.M.G.-S.), Universidad Complutense de Madrid (UCM), Spain
- Departamento de Bioquímica y Biología Molecular (J.M.G.-S.), Universidad Complutense de Madrid (UCM), Spain
| | - Ignacio Lizasoain
- Unidad de Investigación Neurovascular, Departamento de Farmacología, Facultad de Medicina (C.T.-L., M.I.C., A.G.-C., J.d.l.P., S.V.-R., T.J.-F., F.J.d.C.-M., I.L., M.A.M.), Universidad Complutense de Madrid (UCM), Spain
- Instituto Universitario de Investigación en Neuroquímica (C.T.-L., M.I.C., A.G.-C., J.M.G.-S., I.L.), Universidad Complutense de Madrid (UCM), Spain
- Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain (C.T.-L., M.I.C., A.G.-C., I.L., M.A.M.)
| | - María A Moro
- Neurovascular Pathophysiology, Cardiovascular Risk Factor and Brain Function Programme, Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain (C.T.-L., M.I.C., A.G.-C., S.V.-R., T.J.-F., F.J.d.C.-M., O.H., M.A.M.)
- Unidad de Investigación Neurovascular, Departamento de Farmacología, Facultad de Medicina (C.T.-L., M.I.C., A.G.-C., J.d.l.P., S.V.-R., T.J.-F., F.J.d.C.-M., I.L., M.A.M.), Universidad Complutense de Madrid (UCM), Spain
- Instituto de Investigación Hospital 12 de Octubre (i+12), Madrid, Spain (C.T.-L., M.I.C., A.G.-C., I.L., M.A.M.)
| |
Collapse
|